Kallikrein-related peptidase 4 contributes to the tumor metastasis of oral squamous cell carcinoma

被引:13
作者
Cui, Zhi [1 ]
Cui, Ye [2 ]
Luo, Gan [2 ]
Yang, Shuting [3 ]
Ling, Xinlian [2 ]
Lou, Yixin [2 ]
Sun, Xinhua [2 ]
机构
[1] Jilin Univ, Sch Stomatol, Dept Oral & Maxillofacial Surg, Changchun, Jilin, Peoples R China
[2] Jilin Univ, Sch Stomatol, Dept Orthodont, Changchun, Jilin, Peoples R China
[3] Jilin Univ, Sch Stomatol, Dept Prosthodont, Changchun, Jilin, Peoples R China
关键词
invasion; KLK4; migration; OSCC; PI3K; AKT; HUMAN TISSUE KALLIKREINS; PROSTATE-CANCER; GENE FAMILY; EXPRESSION; KLK4; GROWTH; ACTIVATION; PROGNOSIS; ESTROGEN; DISEASE;
D O I
10.1080/09168451.2017.1356216
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Oral squamous cell carcinoma (OSCC) is a disfiguring malignancy and significantly impacts the quality of patient's life. Kallikrein-related peptidase 4 (KLK4), which is closely related to cancers, is highly expressed in OSCC. To explore the biological function of KLK4 in OSCC, a KLK4-specific shRNA was used to silence its endogenous expression, and then the migration and invasion of OSCC cells were explored. Results of our study showed that silencing KLK4 inhibited the migration and invasion of OSCC cells. The protein levels of epithelial mesenchymal transition-associated markers and proteases were also altered by KLK4 silencing. Further study showed that the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway was involved in the function of KLK4. Treatment with a PI3K/AKT activator reversed the migration-inhibitory effect of KLK4 shRNA. Our study suggests that KLK4 may contribute to the metastasis of OSCC through the PI3K/AKT signaling pathway.
引用
收藏
页码:1768 / 1777
页数:10
相关论文
共 32 条
[1]   Plasma Kallikrein Promotes Epidermal Growth Factor Receptor Transactivation and Signaling in Vascular Smooth Muscle through Direct Activation of Protease-activated Receptors [J].
Abdallah, Rany T. ;
Keum, Joo-Seob ;
Lee, Mi-Hye ;
Wang, Bing ;
Gooz, Monika ;
Luttrell, Deirdre K. ;
Luttrell, Louis M. ;
Jaffa, Ayad A. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (45) :35206-35215
[2]  
[Anonymous], 2018, ANTI-CANCER DRUG, DOI [DOI 10.3322/caac.20115, DOI 10.1097/CAD.0000000000000617]
[3]   Kallikrein-Related Peptidase 4 Gene (KLK4) in Prostate Tumors: Quantitative Expression Analysis and Evaluation of Its Clinical Significance [J].
Avgeris, Margaritis ;
Stravodimos, Konstantinos ;
Scorilas, Andreas .
PROSTATE, 2011, 71 (16) :1780-1789
[4]   The emerging roles of human tissue kallikreins in cancer [J].
Borgoño, CA ;
Diamandis, EP .
NATURE REVIEWS CANCER, 2004, 4 (11) :876-890
[5]   The expanded human kallikrein (KLK) gene family:: Genomic organisation, tissue-specific expression and potential functions [J].
Clements, J ;
Hooper, J ;
Dong, Y ;
Harvey, T .
BIOLOGICAL CHEMISTRY, 2001, 382 (01) :5-14
[6]   The tissue kallikrein family of serine proteases: Functional roles in human disease and potential as clinical [J].
Clements, JA ;
Willemsen, NM ;
Myers, SA ;
Dong, Y .
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2004, 41 (03) :265-312
[7]   KLK4 silencing inhibits the growth of oral squamous cell carcinoma through Wnt/β-catenin signaling pathway [J].
Cui, Zhi ;
Cui, Ye ;
Yang, Shuting ;
Luo, Gan ;
Wang, Yang ;
Lou, Yixin ;
Sun, Xinhua .
CELL BIOLOGY INTERNATIONAL, 2017, 41 (04) :392-404
[8]  
Dong Y, 2001, CLIN CANCER RES, V7, P2363
[9]   Kallikrein 4 is a potential mediator of cellular interactions between cancer cells and osteoblasts in metastatic prostate cancer [J].
Gao, Jin ;
Collard, Rachael L. ;
Bui, Loan ;
Herington, Adrian C. ;
Nicoj, David L. ;
Clements, Judith A. .
PROSTATE, 2007, 67 (04) :348-360
[10]   Kallikreins and proteinase-mediated signalling: proteinase-activated receptors (PARs) and the pathophysiology of inflammatory disease and cancer [J].
Hollenberg, Morley D. ;
Oikonomopoulou, Katerina ;
Hansen, Kristina K. ;
Saifeddine, Mahmoud ;
Ramachandran, Rithwik ;
Diamandis, Eleftherios P. .
BIOLOGICAL CHEMISTRY, 2008, 389 (06) :643-651